ALPMF - Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript
2024-02-05 13:08:05 ET
Astellas Pharma Inc. (ALPMF)
Q3 2023 Results Earnings Conference Call
February 5, 2024, 02:00 AM ET
Company Participants
Hiromitsu Ikeda - Corporate Head, Advocacy & Relations
Atsushi Kitamura - Chief Financial Officer
Tadaaki Taniguchi - Chief Medical Officer
Claus Zieler - Chief Commercial Officer
Conference Call Participants
Hidemaru Yamaguchi - Citigroup Securities
Kazuaki Hashiguchi - Daiwa Securities
Shinichiro Muraoka - Morgan Stanley MUFJ Securities
Akinori Ueda - Goldman Sachs Securities
Seiji Wakao - JPMorgan Securities Japan Co., Ltd.
Kasumi Haruta - UBS Securities Japan Co., Ltd.
Koichi Mamegano - BofA Securities Japan Co., Ltd.
Miki Sogi - AlianceBernstein Japan Ltd.
Hiroyuki Matsubara - Nomura Securities Co., Ltd.
Presentation
Hiromitsu Ikeda
Everyone, thank you very much for your participation to this announcement of Q3 FY 2023 Financial Results Ended December 31, 2023. I really appreciate your participation. And I'm Ikeda, I would like to serve as a moderator. My name is Ikeda, Chief Communications and IR Officer. We are going to have presentation first, followed by Q&A session. Japanese-English simultaneous translation is available. However, for that translation, the accuracy is not guaranteed by Astellas. [Operator Instructions].
And today's presentation is based upon the material available on our website. This material or representation by representatives for the company and answers and statement by representatives for the company in the Q&A session includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on the number of factors. Please do understand about that.
And they contain information on pharmaceuticals, including compounds under development, but this information is not intended to make any representations or an advertisement regarding the efficacy or effectiveness.
The participants here today is Atsushi Kitamura, Chief Financial Officer; Yoshitsugu Shitaka, Chief Scientific Officer; Tadaaki Taniguchi, Chief Medical Officer; Claus Zieler, Chief Commercial Officer. We have all those four on the stage.
Now please start the presentation, Kitamura-san.
Atsushi Kitamura
Hello, everyone. I'm Atsushi Kitamura from Astellas Pharma Inc. Thank you very much for joining our FY 2023 third quarter financial results announcement meeting, although we have a very busy schedule today.
This is a cautionary statement regarding forward-looking information. As this was explained by Ikeda earlier, I'm going to skip this page.
Page three is the agenda for today. Starting from the next page, I've explained these topics in this order. On page 4, I will give you an overview of FY 2023 third quarter financial results.
Revenue increased year-on-year, but was behind the full year forecast we revised in the second quarter. XTANDI and XOSPATA was in line with the full year forecast revised upward in the second quarter. PADCEV was in line with the full-year forecast, revised significantly upward in the second quarter. Also, potential peak sales forecast was revised upward, incorporating the robust results of EV-302 study.
On the other hand, regarding VEOZAH, overall initiatives are progressing, but demand trails internal expectations. Full-year forecast was revised downward. IZERVAY demonstrated encouraging first full quarter performance since launch. This progress made us feel confident about its future growth. ...
Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript